Cataract, Refractive Lens Exchange
Conditions
Keywords
cataract, multifocal IOL
Brief summary
The goal of this clinical trial is to learn about the visual performance of a new multifocal intra-ocular lens in patients presenting for cataract or refractive lens exchange surgery. The main question it aims to answer is: What is the visual performance and patient satisfaction twelve months post-operatively? Participants will receive bilateral implantation of the investigational device, undergo post-operative assessments, and provide feedback on their overall visual satisfaction.
Interventions
DEVICEAT ELANA
The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
Sponsors
Carl Zeiss Meditec AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients scheduled for cataract or refractive lens exchange surgery requiring bilateral implantation of multifocal IOL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older; * Patients scheduled for bilateral AT ELANA 841P phacoemulsification cataract extraction or Femtosecond-Laser-Assisted-Cataract-Surgery (cataract grades of 1, 2, 3 on the LOCSIII scale) and IOL implantation (Cataract or PRELEX) with a maximum of 28 days between both implantations; Calculated IOL power within the limited IOL Diopter range of +15.0D to +27.0D * No visual acuity limiting pathologies other than cataract; * Corneal Astigmatism of \<1.0 D; * Availability, willingness, and sufficient cognitive awareness to comply with examination procedures; * Written informed consent for participation in the study and data protection.
Exclusion criteria
* Corneal Astigmatism of ≥1.0 D; * Difficulty for cooperation (distance from their home, general health conditions); * History of acute or chronic disease, pathology, illness, or ocular trauma that would, in the surgeon's opinion, confound results (e.g., corneal pathology, OHT, glaucoma suspect, glaucoma, macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, amblyopia, etc.); * Visual field loss which has an impact on visual acuity; * Use of systemic or ocular medication that might affect vision; * Patients with amblyopia, strabismus, forme fruste keratoconus or keratoconus; * Pupil abnormalities (non-reactive, tonic pupils, abnormal myosis or mydriasis, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions); * Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g., pseudoexfoliation syndrome); * Cataract grades of 4, 5 or 6 on the LOCSIII scale ; * Surgeries with incision size of ≥2.75mm ; * Immediate Sequential Bilateral Cataract Surgery ; * Concurrent participation in another device investigation; * Usage of contact lenses during participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean monocular best-corrected distance visual acuity (CDVA) | Three (3) Months | The objective is to evaluate Corrected Distance Visual Acuity (CDVA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Refractive Predictability / Manifest Refraction and Prediction Error | Twelve (12) Months | Descriptive analysis of the manifest refraction parameters sphere, cylinder, and spherical equivalent (MRSE) will be reported to determine refractive predictability |
Countries
Germany, Spain
Outcome results
None listed